Neurocrine Biosciences’ (NBIX) “Buy” Rating Reaffirmed at Canaccord Genuity Group
Canaccord Genuity Group reissued their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX – Free Report) in a report published on Thursday, Benzinga reports. Canaccord Genuity Group currently has a $150.00 price target on the stock. NBIX has been the topic of several other reports. Cantor Fitzgerald reissued an overweight rating on shares of Neurocrine […]
More Stories
8 Best Commercial Skylight Companies for US Projects (2026)
Getting commercial daylighting wrong is expensive in a way residential work rarely is. A leaking curb on a house is...
Is Sweet Magnolias Season 6 Renewed? Latest News and Review
Netflix’s romantic drama Sweet Magnolias has finally come to an end. In September 2026, Deadline officially announced that one of...
The Inbetweeners 3: Release Date, Cast, Trailer, and Updates
The Inbetweeners 3 is finally coming back on the popular streaming Network, Netflix. The original four stars of the series,...
7 Essential Components of a Modern Corporate Training Tech Stack
What the seven components need to accomplish Your LMS isn’t obsolete. It may simply need to play one part in...
Climate-ready workplaces in 2026: managing heat, flooding, ice and severe weather
Irish and British workplaces are facing severe weather with increasing frequencies, from heatwares and flash flooding to ice underfoot. Preparing...
7 Best Bespoke Smoke Vents for Large and Complex Roof Openings (2026)
Picture a main contractor in Leeds coordinating a logistics warehouse where the structural grid leaves a 2,800 mm clear zone...